Furthermore, the use of conventional intensive chemotherapy in patients with GATA2-related MDS is associated with increased NRM probably because of prolonged episodes of neutropenia adding to the risk of the underlying immunodeficiency (4, 23). This evidence concerns the gene GATA2 and myelodysplastic syndrome.